Periodic Reporting, encompassing Periodic Safety Update Reports (PSURs), Development Safety Update Reports (DSURs), and Addendum to Clinical Overview, is a regulatory requirement that plays a pivotal role in the ongoing assessment of a medicinal product’s risk-benefit balance.

These reports are critical for marketing authorisation holders, as they provide regulatory authorities with an update on the global safety information of a product, reflecting any new risks or changes in the known risk profile.

The preparation and maintenance of these documents are essential during both the clinical development and post-authorisation phases, ensuring that all safety information is accurately captured and analysed.

At Arithmos, we offer comprehensive services in the preparation of pharmacovigilance documents, meticulously aligned with EU legal requirements.

Our expertise includes:

 

 

 

 

Our team ensures that your periodic reports are not only compliant with the latest regulations but also provide a comprehensive analysis that supports the safe and effective use of your medicinal products.